Current ADA guidelines recommend:

• A1C goal for nonpregnant adults of <7% (53 mmol/mol) without significant hypoglycemia is appropriate.


• Achievement of lower A1C levels than 7% may be acceptable, and even beneficial, if achieved safely without significant hypoglycemia or other adverse effects.


• A1C goals of <8% [64 mmol/mol] or higher may be appropriate for patients with limited life expectancy, or where the risks outweigh the benefits.

Current ADA guidelines recommend that the medication regimen and medication-taking behavior should be reevaluated at regular intervals (every 3–6 months) and adjusted as needed to incorporate specific factors that impact treatment choice.



How long after starting a diabetes medication do you wait to see if the patient needs to switch or escalate to other non-insulin anti-diabetic treatments?



What are the key considerations when deciding to switch or escalate to other non-insulin anti-diabetic treatments?

Current ADA guidelines recommend:

• A1C goal for nonpregnant adults of <7% (53 mmol/mol) without significant hypoglycemia is appropriate.


• Achievement of lower A1C levels than 7% may be acceptable, and even beneficial, if achieved safely without significant hypoglycemia or other adverse effects.


• A1C goals of <8% [64 mmol/mol] or higher may be appropriate for patients with limited life expectancy, or where the risks outweigh the benefits.

Current ADA guidelines recommend that the medication regimen and medication-taking behavior should be reevaluated at regular intervals (every 3–6 months) and adjusted as needed to incorporate specific factors that impact treatment choice.



How long after starting a diabetes medication do you wait to see if the patient needs to switch or escalate to other non-insulin anti-diabetic treatments?



What are the key considerations when deciding to switch or escalate to other non-insulin anti-diabetic treatments?

Current ADA guidelines recommend:

• A1C goal for nonpregnant adults of <7% (53 mmol/mol) without significant hypoglycemia is appropriate.


• Achievement of lower A1C levels than 7% may be acceptable, and even beneficial, if achieved safely without significant hypoglycemia or other adverse effects.


• A1C goals of <8% [64 mmol/mol] or higher may be appropriate for patients with limited life expectancy, or where the risks outweigh the benefits.

Current ADA guidelines recommend that the medication regimen and medication-taking behavior should be reevaluated at regular intervals (every 3–6 months) and adjusted as needed to incorporate specific factors that impact treatment choice.



How long after starting a diabetes medication do you wait to see if the patient needs to switch or escalate to other non-insulin anti-diabetic treatments?



What are the key considerations when deciding to switch or escalate to other non-insulin anti-diabetic treatments?

Current ADA guidelines recommend:

• A1C goal for nonpregnant adults of <7% (53 mmol/mol) without significant hypoglycemia is appropriate.
• Achievement of lower A1C levels than 7% may be acceptable, and even beneficial, if achieved safely without significant hypoglycemia or other adverse effects.
• A1C goals of <8% [64 mmol/mol] or higher may be appropriate for patients with limited life expectancy, or where the risks outweigh the benefits.

Current ADA guidelines recommend that the medication regimen and medication-taking behavior should be reevaluated at regular intervals (every 3–6 months) and adjusted as needed to incorporate specific factors that impact treatment choice.

How long after starting a diabetes medication do you wait to see if the patient needs to switch or escalate to other non-insulin anti-diabetic treatments?

What are the key considerations when deciding to switch or escalate to other non-insulin anti-diabetic treatments?

Current ADA guidelines recommend:

• A1C goal for nonpregnant adults of <7% (53 mmol/mol) without significant hypoglycemia is appropriate.


• Achievement of lower A1C levels than 7% may be acceptable, and even beneficial, if achieved safely without significant hypoglycemia or other adverse effects.


• A1C goals of <8% [64 mmol/mol] or higher may be appropriate for patients with limited life expectancy, or where the risks outweigh the benefits.

Current ADA guidelines recommend that the medication regimen and medication-taking behavior should be reevaluated at regular intervals (every 3–6 months) and adjusted as needed to incorporate specific factors that impact treatment choice.



How long after starting a diabetes medication do you wait to see if the patient needs to switch or escalate to other non-insulin anti-diabetic treatments?



What are the key considerations when deciding to switch or escalate to other non-insulin anti-diabetic treatments?